READ MORE:
• Premium - Will Fisher and Paykel Healthcare benefit from the coronavirus outbreak?
• F&P Healthcare shares rally after ResMed deal to drop legal action
• Premium - Why F&P Healthcare continues to break through new highs
• F&P Healthcare ends its golden run after US legal action
F&P Healthcare's old guidance, which assumed a US64c exchange rate, was for revenue of $1.20 billion. Under the revised guidance, assuming an exchange rate of US61c, the figure has risen to $1.24b.
"Assuming a NZ-US exchange rate of approximately US61cs and a NZ-EU exchange rate of approximately 55 cents for the rest of the financial year, the company expects full-year operating revenue to be approximately $1.24 billion and net profit after tax to be within the range of approximately $275 million to $280 million," it said in a statement.
F&P Healthcare's respiratory humidifiers and consumables are directly involved in treating patients with coronavirus.
"We have seen an increase in demand globally and have ramped up our manufacturing output," chief executive Lewis Gradon said.
"At the same time, we have benefited from stronger sales in our Homecare product group and a weakening of the NZ dollar," chief executive Lewis Gradon said.
"We are very appreciative of the support that we have received from our suppliers and from government agencies globally during this challenging time," he said.
Graden said F&P Healthcare employees were working "tirelessly" to manufacture products, support operations and supply and train end-users.
"I know our team is doing everything we can to meet the needs of our customers and the
patients who use our products," Gradon said.
The company's result is due on May 28.